Prurigo nodularis (PN) is a skin condition marked by extremely itchy bumps that form due to repeated scratching, picking, or rubbing. The itch-scratch cycle — where itching prompts scratching, which ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab ...
The itch can be so intense that it causes an uncontrollable urge to scratch and rub, which causes more itching and inflammation. After about six weeks, hard (not pus-filled) nodules appear where the ...
Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25 th World Congress of Dermatology (WCD) in Singapore. The results highlight ...
Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by firm, itchy, and often painful bumps (nodules) on the skin. It typically begins with intense itchiness, which can be ...
Paris and Tarrytown, N.Y. September 28, 2022. The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this ...
The European Commission has approved nemolizumab (Nemluvio) for subcutaneous use in treating moderate to severe atopic dermatitis (AD) in patients aged ≥ 12 years and moderate to severe prurigo ...
Approval represents the second dermatology indication for Dupixent and fifth disease indication overall in the U.S. TARRYTOWN, N.Y. and PARIS, Sept. 28, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results